James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,908,251.64. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond also recently made the following trade(s):

• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Stock Down 0.5%

NASDAQ:UTHR opened at $571.73 on Friday. The stock’s 50-day simple moving average is $516.68 and its 200 day simple moving average is $484.65. The firm has a market capitalization of $25.06 billion, a PE ratio of 20.49, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the firm posted $6.19 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald lifted their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. TD Cowen lifted their price target on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Morgan Stanley lifted their price target on United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $601.50.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Raymond James initiated/covered UTHR with an “outperform” rating and a $700 price target, implying roughly ~22% upside from the recent price — a material bullish catalyst for sentiment and valuing upside. Read More.
• Positive Sentiment: Morgan Stanley raised its price target on UTHR to $519 (from $471), signaling incremental analyst confidence in the shares and helping underpin the stock. Read More.
• Neutral Sentiment: Short‑interest data in the recent report show effectively zero reported short interest (appears anomalous/immaterial), so short‑squeeze dynamics are not a current driver. (Data point reported publicly.)
• Negative Sentiment: CFO James Edgemond sold 10,000 shares (~$5.78M) on April 9 at an average $577.89; the sale was part of a Rule 10b5‑1 plan but reduces his direct stake by ~34.6% — multiple recent 10b5‑1 sales by the CFO may be viewed negatively by some investors. Read More.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.51M) on April 8 at an average $580.45 under a pre‑arranged 10b5‑1 plan; while planned sales limit immediate governance concern, the size and timing add selling weight to headlines. Read More.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in UTHR. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management raised its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the fourth quarter worth approximately $31,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.